Neurocrine Biosciences' Crinecerfont Shows Results in Pediatric CAH Study
Portfolio Pulse from Benzinga Newsdesk
Neurocrine Biosciences announced positive results from its CAHtalyst Pediatric Phase 3 study on crinecerfont for treating congenital adrenal hyperplasia (CAH). The study met primary and key secondary endpoints, showing significant androgen reduction and glucocorticoid dose reduction while maintaining androgen control. The results were published in The New England Journal of Medicine and presented at ENDO 2024.
June 03, 2024 | 11:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurocrine Biosciences' CAHtalyst Pediatric Phase 3 study on crinecerfont met primary and key secondary endpoints, showing significant androgen reduction and glucocorticoid dose reduction while maintaining androgen control. The results were published in The New England Journal of Medicine and presented at ENDO 2024.
The positive results from the CAHtalyst Pediatric Phase 3 study are likely to boost investor confidence in Neurocrine Biosciences. Meeting primary and key secondary endpoints is a significant milestone, and publication in a prestigious journal like The New England Journal of Medicine further validates the study's findings. This could lead to a short-term increase in NBIX's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100